NEJM: Sotorasib has a significant effect in treating late-stage solid tumors with KRAS mutations.

There is currently no approved treatment plan for KRAS mutant tumors, and statistics show that 13% of patients with non-small cell lung cancer (NSCLC) and 1-3% of colorectal cancer and other cancers have KRASG12C mutations.
recently evaluated the efficacy of selective, irreversible targeting of KRASG12C inhibitor Sotorasib.
study is a Phase I clinical trial of Sotorasib's treatment of late-stage solid tumors with KRAS p.G12C mutations.
patients take sotorasib ornation once a day.
end point of the study is safety, and the key secondary endpoint is pharmacodynamics and objective response, which are evaluated according to RECIST.
a total of 129 patients participated in the study, including 59 cases of non-small cell lung cancer, 42 cases of colorectal cancer, 28 cases of other tumors, the previous average of 3 treatments.
toxicity or treatment-related deaths were not observed in the study.
73 patients (56.6%) had treatment-related adverse events and 15 patients (11.6%) had level 3 or 4 events.
In the NSCLC subgroup, 32.2% (19 cases) had a clear objective therapeutic response (full or partial response), 88.1% (52 cases) of patients had a controlled disease (objective response or disease stabilization), and a medium progressive life of 6.3 months.
in the colorectal cancer subgroup, 7.1% (3 cases) had a therapeutic response, 73.8% (31 cases) of patients had a controlled disease, and the medium progressive survival period was 4.0 months.
response was also observed in patients with pancreatic, endometrial, appendicoma and melanoma.
, Sotorasib showed good therapeutic results in patients with advanced solid tumors with KRAS p.G12C mutations.
.